These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 37183664

  • 1. Analysis of the binding pattern of NIK inhibitors by computational simulation.
    Tang Y.
    J Biomol Struct Dyn; 2024 Apr; 42(7):3318-3331. PubMed ID: 37183664
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of nuclear factor kappa B inducing kinase suppresses inflammatory responses and the symptoms of chronic periodontitis in a mouse model.
    Wang J, Wu S, Li Z, Liu L, Pang Y, Wei J.
    Int J Biochem Cell Biol; 2021 Oct; 139():106052. PubMed ID: 34364989
    [Abstract] [Full Text] [Related]

  • 4. Targeting NF-κB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer.
    Pflug KM, Sitcheran R.
    Int J Mol Sci; 2020 Nov 11; 21(22):. PubMed ID: 33187137
    [Abstract] [Full Text] [Related]

  • 5. NIK and IKKbeta interdependence in NF-kappaB signalling--flux analysis of regulation through metabolites.
    Kim HB, Evans I, Smallwood R, Holcombe M, Qwarnstrom EE.
    Biosystems; 2010 Feb 11; 99(2):140-9. PubMed ID: 19909783
    [Abstract] [Full Text] [Related]

  • 6. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway.
    Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K.
    Nature; 1999 Mar 18; 398(6724):252-6. PubMed ID: 10094049
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells.
    Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, Murphy TF, Lim DJ, Li JD.
    Proc Natl Acad Sci U S A; 2001 Jul 17; 98(15):8774-9. PubMed ID: 11438700
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of new NIK inhibitors by discriminatory analysis-based molecular docking and biological evaluation.
    Cheng G, Mei XB, Yan YY, Chen J, Zhang B, Li J, Dong XW, Lin NM, Zhou YB.
    Arch Pharm (Weinheim); 2019 Jul 17; 352(7):e1800374. PubMed ID: 31116887
    [Abstract] [Full Text] [Related]

  • 11. Controlling the fate of NIK: a central stage in noncanonical NF-kappaB signaling.
    Sun SC.
    Sci Signal; 2010 May 25; 3(123):pe18. PubMed ID: 20501935
    [Abstract] [Full Text] [Related]

  • 12. Lipopolysaccharide-induced activation of NF-κB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.
    Bhattacharyya S, Borthakur A, Dudeja PK, Tobacman JK.
    Exp Cell Res; 2010 Nov 15; 316(19):3317-27. PubMed ID: 20466000
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. IKKgamma inhibits activation of NF-kappaB by NIK.
    Kwon WJ, Kim SH, Park YO, Cho M, Kang CD, Lee G, An WG, Joo WH, Kim DW.
    Mol Cells; 2004 Oct 31; 18(2):200-6. PubMed ID: 15528996
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase.
    Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB.
    Nature; 1999 Sep 02; 401(6748):82-5. PubMed ID: 10485710
    [Abstract] [Full Text] [Related]

  • 18. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells.
    Odqvist L, Sánchez-Beato M, Montes-Moreno S, Martín-Sánchez E, Pajares R, Sánchez-Verde L, Ortiz-Romero PL, Rodriguez J, Rodríguez-Pinilla SM, Iniesta-Martínez F, Solera-Arroyo JC, Ramos-Asensio R, Flores T, Palanca JM, Bragado FG, Franjo PD, Piris MA.
    Clin Cancer Res; 2013 May 01; 19(9):2319-30. PubMed ID: 23536439
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.